Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy.
bevacizumab
body mass index
metastatic colorectal cancer
obesity
time to progression
Journal
Contemporary oncology (Poznan, Poland)
ISSN: 1428-2526
Titre abrégé: Contemp Oncol (Pozn)
Pays: Poland
ID NLM: 101233223
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
02
2020
accepted:
13
03
2020
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
10
6
2020
Statut:
ppublish
Résumé
Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in metastatic CRC (mCRC). Whether BMI is a prognostic or predictive factor in mCRC is unclear. We aimed to assess efficacy outcomes according to BMI in patient with metastatic colorectal cancer treated with bevacizumab plus FOLFOX chemotherapy regimen in second-line treatment. The analysis of 237 patients with metastatic colorectal cancer treated with bevacizumab plus FOLFOX in the second line (treated from January 2014 to August 2018) in 4 reference oncological centers in Poland. The median age of the patients was 65 years (range 34-82). The median overall survival (OS) and progression-free survival (PFS) of the all 237 patient was 14.6 and 8.8 months, respectively. Comparison of obese patient (BMI > 30 kg/m Patients with mCRC treated with chemotherapy with bevacizumab in second-line treatment with higher BMI compared with normal weight patients have better prognosis in terms of PFS and OS. In this group, we found no evidence of changes in safety profile depending on BMI. Nevertheless, further large randomized studies are needed to assess the body weight on the effectiveness of chemotherapy in combination with bevacizumab.
Identifiants
pubmed: 32514236
doi: 10.5114/wo.2020.94728
pii: 94728
pmc: PMC7265962
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34-41Informations de copyright
Copyright: © 2020 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2014 Jan 16;370(3):233-44
pubmed: 24428469
PLoS One. 2013 Oct 21;8(10):e77901
pubmed: 24205021
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
J Pers Med. 2019 Feb 07;9(1):
pubmed: 30736475
Eur J Cancer. 2018 Jul;98:1-9
pubmed: 29807237
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
J Natl Cancer Inst. 2006 Nov 15;98(22):1647-54
pubmed: 17105987
Annu Rev Nutr. 2012 Aug 21;32:311-42
pubmed: 22540252
Cancer. 2013 Apr 15;119(8):1528-36
pubmed: 23310947
Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2569-78
pubmed: 19755644
Int J Stroke. 2015 Jan;10(1):99-104
pubmed: 25635277
BMC Gastroenterol. 2019 Mar 27;19(1):46
pubmed: 30917791
Diabetologia. 2003 Nov;46(11):1483-8
pubmed: 14534780
Expert Rev Gastroenterol Hepatol. 2015;9(11):1339-42
pubmed: 26366838
Oncologist. 2010;15(8):819-25
pubmed: 20688807
Gastroenterology. 2010 Jun;138(6):2029-2043.e10
pubmed: 20420944
JAMA. 2013 Jan 2;309(1):71-82
pubmed: 23280227
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):13-16
pubmed: 28069727
J Gastrointest Cancer. 2019 Jun;50(2):214-220
pubmed: 29302856
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):21-29
pubmed: 27986655
Eur J Cancer. 2011 Nov;47(17):2560-7
pubmed: 21803570
J Clin Oncol. 2016 Jan 10;34(2):144-50
pubmed: 26503203
Chin J Cancer Res. 2013 Dec;25(6):689-94
pubmed: 24385696
Clin Colorectal Cancer. 2019 Dec;18(4):e309-e315
pubmed: 31547963
Sci Rep. 2017 Oct 30;7(1):14368
pubmed: 29085005
Int J Obes (Lond). 2005 Nov;29(11):1308-14
pubmed: 15953938
Arch Intern Med. 2005 Jan 10;165(1):55-61
pubmed: 15642875
Eur J Cancer Prev. 2013 Jan;22(1):83-9
pubmed: 22609636
Med Oncol. 2013;30(3):679
pubmed: 23921648